Korea's whitening functional claim splits into two branches
The Enforcement Rule of the Cosmetics Act separates preventing melanin deposition, and so suppressing melasma and freckles, from lightening melanin already deposited. Which branch a product cleared is not visible on the label.
Last checked:
Under Korean cosmetics law, “whitening” is a reviewed functional claim defined in two branches — preventing melanin deposition, and lightening melanin already deposited.
A “melasma ampoule” is not a product type but a market label for ampoules aimed at pigmentation. The only regulated item verifiable from the label is the whitening functional claim — and it is less widely known that this claim is not one thing but two.
The two subparagraphs
Article 2 of the Enforcement Rule of the Cosmetics Act divides the whitening function as follows.
| Subparagraph | Defined function | Point of action |
|---|---|---|
| 1 | Preventing melanin from depositing in the skin, thereby suppressing the formation of melasma, freckles and the like, to assist skin whitening | Before formation |
| 2 | Lightening the colour of melanin already deposited in the skin, to assist skin whitening | After formation |
An expectation about existing pigment and an expectation about future pigment fall under different subparagraphs. Product labelling generally says only “functional cosmetic — whitening”, so which review a product cleared has to be resolved by looking the item up in the MFDS functional cosmetics register.
Reading a published trial figure
Brands sometimes publish human-trial results. What matters before the number is whether the conditions were published with it.
| What to check | What goes wrong without it |
|---|---|
| Testing body | No way to tell whether it was third-party verified |
| Sample size | Small samples give wide ranges around a percentage |
| Trial duration | Different durations are not comparable across products |
| Outcome measure | Instrument measurement and questionnaire rating are different things |
| Control group | Without one, change cannot be attributed to the product |
Of five products checked on 12 August 2026, one published its human trial with the test number, conditions and even a footnote on the upper bound; for the other four, publication could not be confirmed. Not publishing does not mean no trial was run — but a figure that cannot be verified cannot be used in a comparison.
What the literature puts at the base
International consensus work on pigmentary disorders places photoprotection at the base of management, and in melasma specifically there is a sustained argument that protection must extend beyond UV into visible light. A cosmetic whitening claim is more accurately read as sitting on top of that base than as replacing it.
From the source
A melasma ampoule is any ampoule marketed on ingredients such as niacinamide or tranexamic acid for pigmentation concerns, and claiming “whitening” requires MFDS functional review or notification per product.
— 5 Korean Melasma Ampoules — Where Clinical Numbers and Real Reviews Diverge (kbeautyguide, 12 Aug 2026).
Related literature
- Passeron T, et al. Global consensus on the management of melanin hyperpigmentation disorders. J Eur Acad Dermatol Venereol 2026;40(5):760-772. PMID 41362125 → International consensus on managing melanin hyperpigmentation disorders.
- Morgado-Carrasco D, Piquero-Casals J, Granger C, Trullàs C, Passeron T. Melasma — The need for tailored photoprotection to improve clinical outcomes. Photodermatol Photoimmunol Photomed 2022;38(6):515-521. PMID 35229368 → Sets out why melasma outcomes call for photoprotection tailored beyond standard UV filtering.
Sources: Enforcement Rule of the Cosmetics Act, Article 2, subparagraphs 1 and 2 (scope of functional cosmetics). Product values checked on 12 August 2026 against brand websites and Hwahae listings (per the source article). This entry offers no diagnosis or treatment guidance. Last checked 2026-08-24.
Frequently asked questions
Is there one whitening claim in Korean cosmetics law?
There are two. Article 2 of the Enforcement Rule of the Cosmetics Act separately defines a function that prevents melanin deposition and thereby suppresses the formation of melasma and freckles, and a function that lightens melanin already deposited.
Can I take a brand's published human-trial figure at face value?
Only alongside its conditions. Testing body, sample size, trial duration, outcome measure and presence of a control all come first. A percentage published without conditions cannot be compared against another product's figure.
Can cosmetics alone manage melasma?
International clinical literature places photoprotection at the base of pigmentary disorder management and argues for protection extending beyond UV into visible light. Cosmetic use does not replace that base.